Bio-Techne (TECH): filings, insider buys & geopolitical news
TECH geopolitical news and exposure. TECH appears in 0 Geopolitics Alpha notes. No notes are stored for this page yet.
Government contracts
No federal prime contract obligations are matched to Bio-Techne in USAspending.gov for the last five years, and no Department of Defense contract announcements name it in the past year. See the largest government contractors.
TECH share price, last 12 months
Close $72.33 on Sep 15, 2026, +9.7% since Oct 24, 2025 (range $43.30 to $72.33, daily closes).
Company facts
- Ticker
- TECH (NasdaqGS)
- Sector
- Health
- Industry (SEC SIC code)
- Biological Products, (No Diagnostic Substances) (2836)
Industry from the SEC Standard Industrial Classification code on the company's EDGAR filings.
What changed for Bio-Techne (TECH)
- 0 news
- 0 SEC filings
- 0 fund / insider trades
Latest SEC filings
None on record yet.
Latest fund & insider buys and sales
None on record yet.
Held by superinvestors
9 of the tracked billionaire portfolios reported TECH in their latest 13F. 13F data is delayed up to 45 days after quarter end; not advice.
| Manager | % of portfolio | Value | Change | Quarter |
|---|---|---|---|---|
| Ruane Cunniff Ruane Cunniff & Goldfarb | 3.68% | $236.6M | Reduced 1% | Q2 2026 |
| Wally Weitz Weitz Investment Management | 2.66% | $38.4M | Reduced 17% | Q2 2026 |
| Lee Ainslie Maverick Capital | 0.98% | $108.5M | Reduced 68% | Q2 2026 |
| George Soros Soros Fund Management | 0.50% | $37.8M | New position | Q2 2026 |
| Henry Ellenbogen Durable Capital Partners | 0.34% | $35.5M | Reduced 89% | Q2 2026 |
| Bill Gates Cascade Investment | 0.16% | $289.9K | No change | Q3 2026 |
| Larry Robbins Glenview Capital Management | 0.08% | $4.1M | Reduced 69% | Q2 2026 |
| Ray Dalio Bridgewater Associates | 0.01% | $1.9M | Added 348% | Q2 2026 |
| Mario Gabelli GAMCO Investors | 0.00% | $441.6K | New position | Q2 2026 |
Latest geopolitical & market news
None on record yet.
Peers: Biological Products, (No Diagnostic Substances)
| Company | Ticker | Federal contracts, 12 months |
|---|---|---|
| Amgen | AMGN | $126.0M |
| Gilead Sciences | GILD | – |
| Moderna | MRNA | – |
| argenx SE | ARGX | – |
| Revolution Medicines | RVMD | – |
| Biogen | BIIB | – |
| BioNTech SE | BNTX | – |
| Exelixis | EXEL | – |
| Neurocrine Biosciences | NBIX | – |
| Halozyme Therapeutics | HALO | – |
Biggest government contractors in Health: Regeneron Pharmaceuticals ($279.4M), Fresenius Medical Care AG ($236.7M), Emergent BioSolutions ($216.6M), DaVita ($154.5M), Abbott Laboratories ($147.5M), Amgen ($126.0M), Labcorp Holdings ($96.4M), Stryker ($92.5M).
Congressional trades in TECH
Trades in TECH that members of Congress have publicly reported, newest filing first.
No congressional trades are stored for this view yet.
All congressional stock trades →
Geopolitical news for TECH
Everything on TECH, newest first
No original notes are listed on this page yet.
Frequently asked questions
Does Bio-Techne have government contracts?
No federal prime contract obligations are matched to Bio-Techne (TECH) in USAspending.gov for the last five years. Subcontracts are not included.
Where does the contract data come from?
USAspending.gov (the official source of U.S. federal spending data) and the Department of Defense's daily contract announcements. Both are public domain and refreshed daily here.
What geopolitical news affects TECH?
This page lists every Geopolitics Alpha note that names TECH as exposed to an event, with the reason it is exposed.
Has Congress traded TECH?
The table above lists trades in TECH that members of Congress have publicly reported, with a link to each official filing.
Is this investment advice?
No. We show news, exposure and past price moves. Nothing here is a recommendation.